Optimizing Treatment Management Strategies in AL Amyloidosis with CD-38-Directed mAbs
Faculty share insights into the treatment strategies using CD-38-directed monoclonal antibodies in patients with AL amyloidosis.
Source: onclive.com
Page 3 - Nxc 201 News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Nxc 201. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Nxc 201 Today - Breaking & Trending Today
Treatment Strategies Using Monoclonal Antibodies in AL Amyloidosis
Jeffrey Zonder, MD provides an overview of treatment strategies using monoclonal antibodies for the treatment of AL amyloidosis.
Source: onclive.com
NXC-201 Demonstrates Feasibility of BCMA-Directed CAR T-Cell Therapy in Relapsed/Refractory AL Amyloidosis
The novel anti-BCMA CAR T-cell therapy NXC-201 displayed safety and elicited hematologic and organ responses in patients with relapsed/refractory amyloid light chain amyloidosis, including frail patients.
Source: onclive.com
FDA Grants Orphan Drug Designation to NXC-201 for AL Amyloidosis
The FDA has granted orphan drug designation to the next generation BCMA-directed CAR T-cell therapy NXC-201 for the treatment of patients with amyloid light chain amyloidosis.
Source: onclive.com
Immix Biopharma Up 17% On Securing Orphan Drug Designation For NXC-201
Shares of Immix Biopharma, Inc. (IMMX) are up 17% on Thursday due to the announcement that the FDA has designated NXC-201 as an Orphan Drug Designation (ODD) for the treatment of Amyloid Light Chain (AL) Amyloidosis, a life-threatening blood disorder.
Source: rttnews.com